Eli Lily lost a patent infringement appeal at the Chinese Supreme People’s Court last week, 13 years after its initial lawsuit. The Court held that Changzhou Watson Pharmaceutical Co., Ltd. did not infringe Eli Lily’s Chinese Patent No. 91103346.7 directed to olanzapine manufacturing method. Although Eli Lily initially obtained a favorable judgement of infringement and damages of 3.5 million RMB, the Chinese Supreme People’s Court ruling overturned the initial judgement. Notably, the Chinese Supreme People’s Court hired a technical expert from the Patent Reexamination Board of SIPO. see trial video at http://ts.chinacourt.org/1124.html.